Jean-Emmanuel Kurtz1, Xavier Buy2, Frédéric Deschamps3, Erik Sauleau4, Amine Bouhamama5, Maud Toulmonde6, Charles Honoré7, François Bertucci8, Mehdi Brahmi9, Christine Chevreau10, Florence Duffaud11, Justine Gantzer12, Julien Garnon13, Jean-Yves Blay9, Afshin Gangi13. 1. Service d'Oncologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Electronic address: je.kurtz@icans.eu. 2. Département de radiodiagnostic, Institut Bergonié, Bordeaux, France. 3. Département de radiologie interventionnelle, Institut Gustave Roussy, Villejuif, France. 4. Service de Santé publique, Groupe Méthode en recherche clinique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 5. Service de radiologie interventionnelle oncologique, Centre Léon Bérard, Lyon, France. 6. Département de Médecine Oncologique, Institut Bergonié, Bordeaux France. 7. Service de chirurgie viscérale oncologique et sarcomes, Institut Gustave Roussy, Villejuif, France. 8. Département d'Oncologie médicale, Institut Paoli-Calmettes, Marseille, France. 9. Département de médecine oncologique, Centre Léon Bérard, France. 10. Département d'oncologie médicale, IUCT Oncopole, Toulouse, France. 11. Service d'Oncologie médicale, CHU de Marseille et Aix-Marseille Université (AMU) Marseille, France. 12. Service d'Oncologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 13. Service de radiologie interventionnelle, Hôpitaux Universitaires de Strasbourg, France.
Abstract
BACKGROUND: Desmoid tumours (DTs) are rare tumours originating from musculoaponeurotic structures. Although benign, they may be locally aggressive, leading to pain and disability. European Society for Medical Oncology (ESMO) guidelines recommend frontline watchful waiting and medical treatment in progressing tumours. Cryoablation is an interventional radiology technique that is suitable for DT patients (pts) on the basis of repeated cycles of freezing, leading to cell death. METHODS: CRYODESMO-01 (ClinicalTrials.gov Identifier: NCT02476305) is a prospective, open-label, non-randomised, non-comparative, multicenter study assessing cryoablation in non-abdominopelvic progressing DT. Inclusion criteria were: pts ≥18 y.o., confirmed DT accessible to cryoablation (≥90% destruction), measurable lesion conforming to modified response evaluation criteria in solid tumours (mRECIST), progressive disease after ≥2 lines of medical therapy or with functional symptoms/pain, adequate biological parameters, informed consent, and affiliation to a medical insurance scheme. The primary end-point was the non-progression rate at 12 months; secondary end-points included safety, quality of life (QoL), assessment of pain and functional status. FINDINGS: 50 pts were enrolled (78% female) from four French centres and all were treated. The mean age was 41 y.o. (19-73). The median number of prior treatments was 2.00 [1-4] including non-steroidal anti-inflammatory drugs (NSAIDs), hormone therapy, chemotherapy, and anti-angiogenics. Tumour location included limbs (36%), trunk (60%), and cervical area (4%). The median tumour largest diameter was 89 mm. The rate of non-progressing disease at +12 months was 86% [confidence level (CI) 95% 73-94%]. Median PFS was not reached at a median follow-up of 31 months. Grade 1 and 2 toxicity occurred in 32.8% and 44.5% of patients, grade 3-4 in 22% and no Grade 5 toxicity was observed. Cryoablation significantly improved functional status and pain scores. INTERPRETATION: Cryoablation demonstrated feasibility in progressive DT pts. The study met is primary end-point with 86% of non-progressive disease at +12 months, with reduced pain, better functional status, and encouraging long-term disease control.
BACKGROUND:Desmoid tumours (DTs) are rare tumours originating from musculoaponeurotic structures. Although benign, they may be locally aggressive, leading to pain and disability. European Society for Medical Oncology (ESMO) guidelines recommend frontline watchful waiting and medical treatment in progressing tumours. Cryoablation is an interventional radiology technique that is suitable for DT patients (pts) on the basis of repeated cycles of freezing, leading to cell death. METHODS: CRYODESMO-01 (ClinicalTrials.gov Identifier: NCT02476305) is a prospective, open-label, non-randomised, non-comparative, multicenter study assessing cryoablation in non-abdominopelvic progressing DT. Inclusion criteria were: pts ≥18 y.o., confirmed DT accessible to cryoablation (≥90% destruction), measurable lesion conforming to modified response evaluation criteria in solid tumours (mRECIST), progressive disease after ≥2 lines of medical therapy or with functional symptoms/pain, adequate biological parameters, informed consent, and affiliation to a medical insurance scheme. The primary end-point was the non-progression rate at 12 months; secondary end-points included safety, quality of life (QoL), assessment of pain and functional status. FINDINGS: 50 pts were enrolled (78% female) from four French centres and all were treated. The mean age was 41 y.o. (19-73). The median number of prior treatments was 2.00 [1-4] including non-steroidal anti-inflammatory drugs (NSAIDs), hormone therapy, chemotherapy, and anti-angiogenics. Tumour location included limbs (36%), trunk (60%), and cervical area (4%). The median tumour largest diameter was 89 mm. The rate of non-progressing disease at +12 months was 86% [confidence level (CI) 95% 73-94%]. Median PFS was not reached at a median follow-up of 31 months. Grade 1 and 2 toxicity occurred in 32.8% and 44.5% of patients, grade 3-4 in 22% and no Grade 5 toxicity was observed. Cryoablation significantly improved functional status and pain scores. INTERPRETATION: Cryoablation demonstrated feasibility in progressive DT pts. The study met is primary end-point with 86% of non-progressive disease at +12 months, with reduced pain, better functional status, and encouraging long-term disease control.
Authors: Pierre Auloge; Julien Garnon; Joey Marie Robinson; Marie-Aude Thenint; Guillaume Koch; Jean Caudrelier; Julia Weiss; Roberto Luigi Cazzato; Jean Emmanuel Kurtz; Afshin Gangi Journal: Int J Clin Oncol Date: 2021-03-11 Impact factor: 3.402
Authors: Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami Journal: Diagnostics (Basel) Date: 2022-05-24
Authors: Stefano Testa; Nam Q Bui; Gregory W Charville; Raffi S Avedian; Robert Steffner; Pejman Ghanouni; David G Mohler; Kristen N Ganjoo Journal: Cancers (Basel) Date: 2022-08-12 Impact factor: 6.575
Authors: Bimal Mayur Kumar Vora; Peter L Munk; Nagavalli Somasundaram; Hugue A Ouellette; Paul I Mallinson; Adnan Sheikh; Hanis Abdul Kadir; Tien Jin Tan; Yet Yen Yan Journal: PLoS One Date: 2021-12-23 Impact factor: 3.240